» Articles » PMID: 28219717

Effects of Tetrahydrocannabinol on Glucose Uptake in the Rat Brain

Overview
Specialties Neurology
Pharmacology
Date 2017 Feb 22
PMID 28219717
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Δ-Tetrahydrocannabinol (THC) is the psychoactive component of the plant Cannabis sativa and acts as a partial agonist at cannabinoid type 1 and type 2 receptors in the brain. The goal of this study was to assess the effect of THC on the cerebral glucose uptake in the rat brain. 21 male Sprague Dawley rats (12-13 w) were examined and received five different doses of THC ranging from 0.01 to 1 mg/kg. For data acquisition a Focus 120 small animal PET scanner was used and 24.1-28.0 MBq of [F]-fluoro-2-deoxy-d-glucose were injected. The data were acquired for 70 min and arterial blood samples were collected throughout the scan. THC, THC-OH and THC-COOH were determined at 55 min p.i. Nine volumes of interest were defined, and the cerebral glucose uptake was calculated for each brain region. Low blood THC levels of < 1 ng/ml (injected dose: ≤ 0.01 mg/kg) corresponded to an increased glucose uptake (6-30 %), particularly in the hypothalamus (p = 0.007), while blood THC levels > 10 ng/ml (injected dose: ≥ 0.05 mg/kg) coincided with a decreased glucose uptake (-2 to -22 %), especially in the cerebellar cortex (p = 0.008). The effective concentration in this region was estimated 2.4 ng/ml. This glucose PET study showed that stimulation of CB1 receptors by THC affects the glucose uptake in the rat brain, whereby the effect of THC is regionally different and dependent on dose - an effect that may be of relevance in behavioural studies.

Citing Articles

Bidirectional Effect of Long-Term Δ-Tetrahydrocannabinol Treatment on mTOR Activity and Metabolome.

Bilkei-Gorzo A, Schurmann B, Schneider M, Kraemer M, Nidadavolu P, Beins E ACS Pharmacol Transl Sci. 2024; 7(9):2637-2649.

PMID: 39296258 PMC: 11406684. DOI: 10.1021/acsptsci.4c00002.


Molecular Findings Guiding the Modulation of the Endocannabinoid System as a Potential Target to Treat Schizophrenia.

Zuccoli G, Brandao-Teles C, Vieira G, Gomes F, Crunfli F Adv Exp Med Biol. 2022; 1400:89-103.

PMID: 35930228 DOI: 10.1007/978-3-030-97182-3_7.


THC and CBD affect metabolic syndrome parameters including microbiome in mice fed high fat-cholesterol diet.

Gorelick J, Assa-Glazer T, Zandani G, Altberg A, Sela N, Nyska A J Cannabis Res. 2022; 4(1):27.

PMID: 35644678 PMC: 9150295. DOI: 10.1186/s42238-022-00137-w.


Effects of Δ9-Tetrahydrocannibinol (THC) on Obesity at Different Stages of Life: A Literature Review.

Fearby N, Penman S, Thanos P Int J Environ Res Public Health. 2022; 19(6).

PMID: 35328862 PMC: 8951828. DOI: 10.3390/ijerph19063174.


Astrocyte Bioenergetics and Major Psychiatric Disorders.

Maly I, Morales M, Pletnikov M Adv Neurobiol. 2021; 26:173-227.

PMID: 34888836 DOI: 10.1007/978-3-030-77375-5_9.